CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Wanbury Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Wanbury Ltd
'B' Wing, 10th Floor, BSEL Techpark
Opp. Vashi Railway Station, Sector 30A
Phone: +91 2267942222p:+91 2267942222 NAVI MUMBAI, 400703  India Ticker: WANBURYWANBURY
Business Summary
Wanbury Limited is an India-based pharmaceutical company. The Company is engaged in the business of pharmaceutical and related activities, including research. The Company operates through two divisions: the Active Pharmaceutical Ingredients (API) Business and the Domestic Formulations Business. The Company, through the Active Pharmaceutical Ingredients (API) Business, provides Metformin and Sertraline. Metformin is used for the treatment for type 2 diabetes and Sertraline is an anti-depressant. It has approximately 13 API products. It manufactures Metformin with over 8500 tons per year. Its products include Metformin HCL, Metformin DC/SR, Sertraline, Diphenhydramine, Mefenamic Acid, Glucosamine, Methoxsalen and Paroxetine. The Company's subsidiaries include Wanbury Holdings B. V. (Netherland), Wanbury Global FZE (UAE), Ningxia Wanbury Fine Chemicals Co. Ltd. (China) and Cantabria Pharma S. L. (Spain).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/20233/31/2023Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
6719 Offices of holding companies, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Vice Chairman of the Board K.Chandran 63 1/1/2015
Chief Financial Officer VinodVerma 5/18/2016 5/18/2016
Compliance Officer, Company Secretary Jitendra J.Gandhi 1/1/2021 4/20/2015
Non-Executive Independent Director Pravin D.Pawar 11/18/2023 11/18/2023
Non-Executive Independent Director AnupamaVaidya 3/17/2022 3/17/2022

Business Names
Business Name
Cantabria Pharma S. L.
Laboratories Wanbury S. L.
Ningxia Wanbury Fine Chemicals Company Limited
4 additional Business Names available in full report.

General Information
Number of Employees: 1,582 (As of 3/31/2023)
Outstanding Shares: 32,745,498 (As of 10/20/2023)
Shareholders: 11,911
Stock Exchange: NSE
Fax Number: +91 2267942111


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, April 27, 2024